2/5
09:12 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/27
05:58 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/24
05:10 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/15
06:06 am
tars
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Low
Report
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
12/11
06:29 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/8
06:06 pm
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $100.00 price target on by analysts at Barclays PLC.
Medium
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $100.00 price target on by analysts at Barclays PLC.
12/5
09:32 am
tars
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]
Low
Report
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]
11/24
04:30 pm
tars
Tarsus to Participate in Upcoming Investor Conference
Medium
Report
Tarsus to Participate in Upcoming Investor Conference
11/20
01:57 pm
tars
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]
Low
Report
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]
11/20
08:43 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $100.00 price target on the stock.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $100.00 price target on the stock.
11/8
01:12 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at
Wall St
Medium
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at
Wall St